Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.59 |
| ▸ | CDK2 | P24941 | 14/20 | 0.59 |
| ▸ | CCND1 | P24385 | 11/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305259 | 1.00 | MAPK14 (0.62) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3308727 | 0.85 | MAPK14 (0.54) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL7797648 | 0.85 | MAPK14 (0.54) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL7794897 | 0.81 | MAPK8 (0.73) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL3305016 | 0.81 | MAPK8 (0.73) | MAPK14CCNE1CDK2CCND1CDK6 | |
| SCHEMBL6336324 | 0.80 | MAPK14 (0.79) | MAPK14MAPK8MAPK9MAPK10FGFR1 | |
| SCHEMBL6336323 | 0.80 | MAPK14 (0.79) | MAPK14MAPK8MAPK9MAPK10FGFR1 | |
| SCHEMBL14014916 | 0.80 | MAPK14 (0.61) | MAPK14MAPK8MAPK9MAPK10FGFR1 | |
| SCHEMBL5114894 | 0.78 | MAPK14 (0.80) | MAPK14MAPK8MAPK9MAPK10 | |
| SCHEMBL14014164 | 0.78 | MAPK14 (0.80) | MAPK14MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2010046273-A2 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | MAP3K20, MAP3K6, MAP3K1 | MAPK14 34/4885CCNE1 725/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.